Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04769947
Other study ID # ITALY-TFR
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 9, 2021
Est. completion date February 8, 2030

Study information

Verified date May 2021
Source University of Turin, Italy
Contact Carmen Fava, MD, PhD
Phone 0115085523
Email carmen.fava@unito.it
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The investigator propose an extension of the previous National, multicentric study, promoting an observational registry, both retrospective and prospective, in order to expand and further characterize the series of Italian patients with Philadelphia-positive, chronic phase CML (CP-CML) who discontinue TKIs in an off-protocol setting. As safety concerns may arise for patients receiving long-term treatments, and due to the growing number of patients discontinuing TKIs in clinical practice, the study aim to collect all available data regarding feasibility and freedom from progression of the cohort of patients.


Description:

This is an observational, retrospective and prospective study of CP-CML patients who discontinue TKIs in Italy. The study will not imply additional costs for the participating centers. Data already present in the clinical charts will be collected. The patients, answering to inclusion/exclusion criteria will be enrolled in one of the follow cohorts - Cohort 1 retrospective/prospective study: 293 patients enrolled and reported in Fava et al 2019 with at least 1 year of follow up at the end of the study (February 2017) and 107 patients enrolled but not reported in Fava et al 2019 since their follow-up was shorter than 1 year. The data for these patients will be collected since the end of previous study. - Cohort 2 retrospective/prospective study: patient not enrolled in the previous study (Fava et al 2019). The data for these patients will be collected since patient diagnosis to the end of the study. - Cohort 3 prospective study: patients who have discontinued TKI therapy after the study approval in each center. These patients will also participate in the validation process of Phase 2 of a questionnaire developed by an expert panel of eight CML patients with the purpose of capturing the experiences of people along all phases of the TFR. Patients participating in the study will not be subjected to any procedure that falls outside the clinical practice; in the same way, clinical variables that will be collected for the study are those that are commonly collected by physician in daily clinical practice. Any decision about drug administration or suspension is made by the physician based on his clinical judgment in the context of clinical practice, independently from decision to include the patient in this study. Registration of enrolled patients will be done on-line on a key restricted accessible web-database. Primary objective and endpoint To assess the TFR rate at 1 year from discontinuation of TKIs. Secondary objectives and endpoints - To further describe the observed population of patients in terms of: - treatment-free duration; o survival in MR4.5; - survival in MR3; - event-free survival; - progression-free survival; - deaths after treatment discontinuation; - rate of achievement of MMR and DMR after treatment re-initiation - To identify clinical and biological prognostic factors affecting the persistence of off-therapy remission. - To identify optimal timing and modalities of molecular monitoring of BCR-ABL1 transcript - Evaluation of the safe minimum monitoring during and after treatment discontinuation - Evaluation of the maximum MRD positivity level acceptable to safely stay off-treatment - Evaluation of short-term adverse events (withdrawal syndrome: fever, arthralgia, myalgia, bone pain, weight loss) after treatment discontinuation - Evaluation of long-term adverse events (i.e. cardiovascular adverse events, second neoplasia) after treatment discontinuation - Validation of the Italian version of the "Phase 2" of a questionnaire developed by an expert panel of eight CML patients to capture the experiences of people along all phases of the TFR - Evaluation of patient-reported outcomes describing quality of life of patients off therapy and after resumption of TKIs


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date February 8, 2030
Est. primary completion date July 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with CP-CML, treated with TKI monotherapy or TKI in association with other drugs (such as interferon, BCR-ABL1 peptidic vaccine and others) - Treatment with TKI discontinued for any reason - Deep Molecular Response (DMR), defined as MR4 (BCR-ABL1 ratio = 0.01% with at least 10,000 ABL1 copies), or MR4.5 (BCR-ABL1 ratio = 0.0032% with at least 32,000 ABL1 copies), or MR5 (BCR-ABL1 ratio = 0.001% with at least 100,000 ABL1 copies), confirmed at least three times before TKI discontinuation. In patients who discontinued TKIs before the establishment of molecular standardization, DMR will be defined as a level of BCR-ABL1 transcript undetectable by qPCR or by qualitative PCR, confirmed in at least two controls. - Participant is willing and able to give informed consent for participation in the study Data regarding patients discontinuing in less than DMR (as defined above) will be collected and analysed separately. Exclusion Criteria: - Patients who were diagnosed with accelerated or blastic phase CML will be excluded

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Division of Hematology-AO Mauriziano Hospital, University of Turin Turin

Sponsors (1)

Lead Sponsor Collaborator
University of Turin, Italy

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary TFR rate at 1 year from discontinuation of TKIs To assess the TFR rate at 1 year from discontinuation of TKIs 1 year
Secondary Secondary objectives treatment-free duration (months); survival in MR4.5 (%); survival in MR3 (%); event-free survival (%); progression-free survival (%); deaths after treatment discontinuation (%); rate of achievement of MMR and DMR after treatment re-initiation (%) 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT02057185 - Occupational Status and Hematological Disease
Recruiting NCT03326310 - Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Phase 1
Recruiting NCT04621851 - Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Completed NCT01207440 - Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 2
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Active, not recruiting NCT02917720 - 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients Phase 2
Not yet recruiting NCT02883036 - Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia N/A
Withdrawn NCT01188889 - RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Phase 1/Phase 2
Completed NCT01795716 - Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body Phase 1
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Approved for marketing NCT00905593 - Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Phase 3
Terminated NCT00573378 - Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia Phase 2
Completed NCT00469014 - Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT00257647 - Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) N/A
Completed NCT00219739 - STI571 ProspectIve RandomIzed Trial: SPIRIT Phase 3
Completed NCT06148493 - Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed NCT00375219 - Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Phase 2